Based on these observations and as mutations of the ALK tyrosine kinase domain constitute an important potential therapeutic target, a program to identify the presence of ALK mutation in the peripheral blood of NB patients showing a high risk of relapse 20 was initiated: the F1174 and R1275 hotspots of ALK gene were investigated using the ddPCR system. Here, ALK is linked to neuroblastoma.